{"id":590598,"date":"2026-08-20T14:22:32","date_gmt":"2026-08-20T14:22:32","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/590598\/"},"modified":"2026-08-20T14:22:32","modified_gmt":"2026-08-20T14:22:32","slug":"a-shot-in-the-arm-for-htt-lowering-insightt-trial-begins-testing-srp-1005-hdbuzz","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/590598\/","title":{"rendered":"A shot in the arm for HTT lowering: INSIGHTT trial begins testing SRP-1005 \u2013 HDBuzz"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Another huntingtin (HTT) lowering drug has officially entered the clinic. The INSIGHTT study has begun dosing participants with SRP-1005, an experimental treatment developed by Sarepta Therapeutics that aims to reduce production of the HTT protein.<\/p>\n<p class=\"wp-block-paragraph\">There are already several different approaches to lowering HTT being tested in people. What sets SRP-1005 apart is how it is delivered. Rather than requiring brain surgery or delivery of a drug into the spinal fluid, SRP-1005 is given by an injection under the skin.<\/p>\n<p class=\"wp-block-paragraph\">This trial is just beginning, so whether SRP-1005 will be safe or effective for people with Huntington\u2019s disease (HD) remains to be seen. But getting another type of HTT-lowering technology into clinical testing gives the HD community another shot on goal and could help researchers learn how to make these treatments easier to deliver.<\/p>\n<p>Same target, but a different way to get there<\/p>\n<p class=\"wp-block-paragraph\">HD is caused by a change in the HTT gene, which contains the instructions for making the HTT protein. The expanded form of HTT is thought to drive many of the harmful changes that occur in HD, making lowering HTT an attractive therapeutic strategy.<\/p>\n<p class=\"wp-block-paragraph\">Researchers are tackling this problem from several different angles. Some approaches use antisense oligonucleotides, or ASOs, which are delivered into the spinal fluid. Others use gene therapy, which requires a one-time neurosurgical procedure to deliver genetic instructions directly into the brain. There are also oral HTT-lowering drugs, which are designed to alter how the HTT genetic message is processed.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/08\/codev-2024-05-17-a20cbd8ca7-shutterstock_2460303701-1024x1024.jpg\" alt=\"\" class=\"wp-image-5925\"  \/>SRP-1005 can stop the HTT genetic message in its tracks, meaning that less HTT protein is made. <\/p>\n<p class=\"wp-block-paragraph\">SRP-1005 adds another technology to this growing toolbox: small interfering RNA, or siRNA. RNA might sound familiar to regular HDBuzz readers. The HTT gene is made of DNA, but cells first copy those genetic instructions into a temporary RNA message called messenger RNA, or mRNA. That message is then used to make the HTT protein.<\/p>\n<p class=\"wp-block-paragraph\">siRNA molecules are designed to recognise particular RNA messages and trigger their destruction. SRP-1005 targets HTT mRNA, with the aim of reducing the amount of HTT protein that cells produce.<\/p>\n<p>Why this new delivery approach matters<\/p>\n<p class=\"wp-block-paragraph\">One of the biggest challenges for drugs that target HTT RNA is getting them to the right place. The brain is protected by the blood-brain barrier, which is excellent at keeping potentially harmful substances out. But it\u2019s also frustratingly good at keeping many potential medicines out too. This is one reason some experimental HD therapies have had to be administered directly into the spinal fluid or brain.<\/p>\n<p class=\"wp-block-paragraph\">SRP-1005 is designed to tackle this problem differently. Sarepta is developing the drug to reach the brain following an injection into the tissue just beneath the skin, known as subcutaneous injection. SRP-1005 can hitch a ride across the blood-brain barrier by binding to a protein called the transferrin receptor, which normally helps transport iron into the brain.<\/p>\n<p>For now, another HTT-lowering strategy entering human testing means another opportunity to learn, and another shot on goal for the HD community<\/p>\n<p class=\"wp-block-paragraph\">The INSIGHTT trial is therefore testing not only a new HTT-lowering molecule, but a potentially important new way of delivering this type of medicine.If this approach ultimately works, it could have practical implications for people with HD. A treatment given by this type of injection could potentially be less invasive and burdensome than repeated spinal injections or brain surgery.<\/p>\n<p class=\"wp-block-paragraph\">There is an important distinction, though: this early trial still involves lumbar puncture procedures so researchers can measure SRP-1005 in cerebrospinal fluid (CSF). The potential promise here is therefore about how the treatment itself is delivered, rather than INSIGHTT being a procedure-free study. CSF is still one of the best windows we have into brain health, HD-related changes, and any improvements in response to an experimental therapy.\u00a0\u00a0<\/p>\n<p>What will INSIGHTT tell us?<\/p>\n<p class=\"wp-block-paragraph\">INSIGHTT is a small, first-in-human Phase 1 study. According to the current clinical trial record, researchers plan to enrol approximately 32 people, aged 21 to 70, who have undergone genetic testing for HD\u00a0 and are classified as <a href=\"https:\/\/en.hdbuzz.net\/325\/\" rel=\"nofollow noopener\" target=\"_blank\">HD-ISS<\/a> Stage 2 or mild Stage 3. The study is currently only recruiting in New Zealand, with additional study centres expected to be activated later on.<\/p>\n<p class=\"wp-block-paragraph\">Participants will be assigned to receive SRP-1005 or placebo across four groups, with each new group receiving a higher dose than the one before it. Conducting an early trial with this type of \u201cdose escalation\u201d design can help to identify the right amount of drug as safely as possible. Treatment consists of three weekly subcutaneous injections, followed by monitoring through 24 weeks.<\/p>\n<p class=\"wp-block-paragraph\">At this stage, the big question is safety, not whether SRP-1005 improves HD symptoms. Researchers will carefully track side effects and will also measure the amount of SRP-1005 found in blood, urine and CSF to see how well the drug spreads through the body. The study is expected to run through late 2027.<\/p>\n<p>More shots on goal<\/p>\n<p class=\"wp-block-paragraph\">The history of HD drug development has taught us not to put all our eggs in one basket. Even treatments aimed at the same fundamental target, like HTT, can differ enormously in how they work, where they travel in the brain, how long their effects last, and how they are administered. That makes having multiple approaches in development a strength rather than unnecessary duplication. Every carefully designed clinical trial can teach the field something, including trials of drugs that ultimately aren\u2019t good treatments for HD.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"2560\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/08\/codev-2021-08-13-850cf97aa5-DNA_in_syringe-edited-scaled.jpg\" alt=\"\" class=\"wp-image-66312\" style=\"aspect-ratio:0.9014063842719708;width:596px;height:auto\"  \/>HTT lowering drugs which can be given by a simple injection could be a game changer for many HD families who don\u2019t have access to advanced neurology care. <\/p>\n<p class=\"wp-block-paragraph\">SRP-1005 is still at the very beginning of that journey. We don\u2019t yet know how well it reaches different parts of the human brain, how much HTT it can lower, what dose will be appropriate, or whether repeated treatment will ultimately prove safe and beneficial. But INSIGHTT expands the range of technologies being tested against one of HD\u2019s most important drug targets. If HTT lowering is going to become a long-term treatment for people with HD, effectiveness is only part of the equation. How safely, conveniently and equitably a treatment can be delivered will matter too.<\/p>\n<p class=\"wp-block-paragraph\">For now, another HTT-lowering strategy entering human testing means another opportunity to learn, and another shot on goal for the HD community.<\/p>\n<p>Learn more: <\/p>\n<p class=\"wp-block-paragraph\" style=\";display:none\">Full details of the INSIGHTT study including current eligibility criteria and recruiting locations, is available from <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07536061\" rel=\"nofollow noopener\" target=\"_blank\">ClinicalTrials.gov under study NCT07536061<\/a>.<\/p>\n<p>Summary:\u00a0<\/p>\n<p>The INSIGHTT Phase 1 trial has begun dosing SRP-1005, a new experimental treatment designed to lower production of the huntingtin (HTT) protein.<\/p>\n<p>SRP-1005 uses siRNA to target HTT messenger RNA, adding another distinct approach to the growing range of HTT-lowering strategies being tested in people.<\/p>\n<p>Unlike treatments delivered into the spinal fluid or directly into the brain, SRP-1005 is given by injection under the skin, potentially offering a less invasive and burdensome treatment option if the approach proves successful.<\/p>\n<p>INSIGHTT will enrol around 32 participants and is primarily testing safety and tolerability. It\u2019s early days, but another modality in clinical testing means another valuable shot on goal for the HD community.<\/p>\n<p>Support HDBuzz<\/p>\n<p class=\"wp-block-paragraph\">Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community.<\/p>\n<p class=\"wp-block-paragraph\">With your support, we can ensure the continuity of our services. Nothing is expected, but everything is appreciated and sustains what we do at HDBuzz. Please consider giving what you\u2019re able.<\/p>\n","protected":false},"excerpt":{"rendered":"Another huntingtin (HTT) lowering drug has officially entered the clinic. The INSIGHTT study has begun dosing participants with&hellip;\n","protected":false},"author":2,"featured_media":590599,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-590598","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/590598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=590598"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/590598\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/590599"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=590598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=590598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=590598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}